Cytosorbents (NASDAQ:CTSO) Stock Rating Upgraded by WBB Securities

Cytosorbents (NASDAQ:CTSO) was upgraded by equities research analysts at WBB Securities to a “moderate buy” rating in a report released on Wednesday, Zacks reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $74.83.

Cytosorbents Stock Up 0.6%

Shares of NASDAQ CTSO opened at $5.35 on Wednesday. The stock has a market capitalization of $16.86 million, a P/E ratio of -0.92 and a beta of 1.37. Cytosorbents has a one year low of $2.84 and a one year high of $17.28. The firm’s 50 day simple moving average is $5.61 and its two-hundred day simple moving average is $8.11. The company has a debt-to-equity ratio of 4.70, a current ratio of 0.66 and a quick ratio of 0.50.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.73. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The firm had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. As a group, analysts expect that Cytosorbents will post -4.40 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Chan acquired 200,000 shares of the stock in a transaction on Friday, September 4th. The stock was purchased at an average price of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer owned 1,944,432 shares of the company’s stock, valued at $680,551.20. This trade represents a 11.47% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.80% of the stock is owned by company insiders.

Cytosorbents Company Profile

CytoSorbents Corporation is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems.